| Website | vlstcorp.com |
| Category | BioTech |
| Phone | 206-262-5500 |
| info@vlstcorp.com | |
| Employees |
| TOTAL | $55M |
| FUNDING TOTAL | $55M |
| Series B, 6/06 Texas Pacific Group MPM Capital ARCH Venture Partners OVP Venture Partners Amgen Ventures MedImmune Ventures WRF Capital | $55M |
VLST Corporation is a privately held biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics, to identify viral genes whose protein products function as immunomodulatory agents. The resulting product candidates will be either human homologues to these virulence factors or monoclonal antibodies that mimic the function of the virulence gene products. This approach allows for the efficient identification of high quality, pre-validated drug targets for the treatment of autoimmune and inflammatory disorders. The Company’s technology has identified potential product candidates for the treatment of disorders such as multiple sclerosis, lupus, psoriasis, rheumatoid arthritis and diabetes.
